Erythromycin ethyl succinate

The main ingredient of this product is erythromycin ethylsuccinate.

1. This product can inhibit the metabolism of anti-epileptic drugs such as carbamazepine and valproic acid, resulting in increased blood concentrations and toxic reactions. Combination with fentanyl can inhibit the metabolism of the latter and prolong its duration of action. Combination with antihistamines such as astemizole or terfenadine can increase cardiac toxicity, and combination with cyclosporine can increase the latter's blood concentration and produce nephrotoxicity. 2. This product has an antagonistic effect with chloramphenicol and lincosamides, and it is not recommended to use them at the same time. 3. This product is an antibacterial agent and can interfere with the bactericidal efficacy of penicillin. Therefore, when a rapid bactericidal effect is required, such as the treatment of meningitis, the two should not be used at the same time. 4. Patients who take warfarin for a long time may prolong the prothrombin time when using this product, thereby increasing the risk of bleeding. Elderly patients should pay special attention. When the two must be used at the same time, the dose of warfarin should be appropriately adjusted and the prothrombin time should be closely observed. 5. Except for dihydroxypropylphylline, the simultaneous use of this product with xanthine drugs can reduce the hepatic clearance of aminophylline, leading to increased serum aminophylline concentrations and increased toxic reactions. This phenomenon is more likely to occur after the combined use, and the reduction in aminophylline clearance is proportional to the serum peak value of this product. Therefore, the dose of xanthine drugs should be adjusted during and after the combination of the two. 6. The combination of this product with other hepatotoxic drugs may enhance hepatotoxicity. 7. The combination of large doses of this product with ototoxic drugs, especially in patients with renal impairment, may increase ototoxicity. 8. When used in combination with lovastatin, its metabolism can be inhibited and the blood concentration can be increased, which may cause rhabdomyolysis; when used in combination with midazolam or triazolam, the clearance of both can be reduced and their effects can be enhanced.

Erythromycin ethylsuccinate.

1. This product can inhibit the metabolism of anti-epileptic drugs such as carbamazepine and valproic acid, resulting in increased blood concentrations and toxic reactions. Combination with alfentanil can inhibit the metabolism of the latter and prolong its duration of action. Combination with antihistamines such as astemizole or terfenadine can increase cardiac toxicity, and combination with cyclosporine can increase the latter's blood concentration and produce nephrotoxicity. 2. This product has an antagonistic effect with chloramphenicol and lincosamides, and it is not recommended to use them at the same time. 3. This product is an antibacterial agent and can interfere with the bactericidal efficacy of penicillin. Therefore, when rapid bactericidal effects are required, such as the treatment of meningitis, the two should not be used at the same time. 4. Patients who take warfarin for a long time may prolong the prothrombin time when using this product, thereby increasing the risk of bleeding. Elderly patients should pay special attention. When the two must be used at the same time, the dose of warfarin should be appropriately adjusted and the prothrombin time should be closely observed. 5. Except for dihydroxypropylphylline, the simultaneous use of this product with xanthine drugs can reduce the hepatic clearance of aminophylline, leading to increased serum aminophylline concentrations and (or) increased toxic reactions. This phenomenon is more likely to occur after 6 days of combined use, and the reduction in aminophylline clearance is proportional to the serum peak value of this product. Therefore, the dose of xanthine drugs should be adjusted during and after the combination of the two. 6. Combination with other hepatotoxic drugs may enhance hepatotoxicity. 7. The combination of large doses of this product with ototoxic drugs, especially in patients with renal impairment, may increase ototoxicity. 8. When used in combination with lovastatin, its metabolism can be inhibited and the blood concentration can be increased, which may cause rhabdomyolysis; when used in combination with midazolam or triazolam, the clearance of both can be reduced and their effects can be enhanced.

The main ingredient of this product is erythromycin ethylsuccinate.

1. This product can inhibit the metabolism of antiepileptic drugs such as carbamazepine and valproic acid, resulting in increased blood concentrations and toxic reactions. Combination with alfentanil can inhibit the metabolism of the latter and prolong its duration of action. Combination with antihistamines such as astemizole or terfenadine can increase cardiac toxicity, and combination with cyclosporine can increase the latter's blood concentration and produce nephrotoxicity. 2. It has an antagonistic effect on chloramphenicol and lincomycin, and it is not recommended to use them at the same time. 3. This product is an antibacterial agent and can interfere with the bactericidal efficacy of penicillin. Therefore, when rapid bactericidal effects are required, such as the treatment of meningitis, the two should not be used at the same time. 4. Patients who take warfarin for a long time can prolong the prothrombin time when using this product, thereby increasing the risk of bleeding. Elderly patients should pay special attention. When the two must be used at the same time, the dose of warfarin should be appropriately adjusted and the prothrombin time should be closely observed. 5. Except for dihydroxypropylphylline, the simultaneous use of this product with xanthine drugs can reduce the hepatic clearance of aminophylline, leading to an increase in serum aminophylline concentration and (or) increased toxic reactions. This phenomenon is more likely to occur after 6 days of co-use, and the reduction in aminophylline clearance is proportional to the serum peak of this product. Therefore, the dose of xanthine drugs should be adjusted when and after the two are used together. 6. Combination with other hepatotoxic drugs may enhance hepatotoxicity. 7. Large doses of this product combined with ototoxic drugs, especially in patients with renal impairment, may increase ototoxicity. 8. When used in combination with lovastatin, it can inhibit its metabolism and increase blood concentration, which may cause rhabdomyolysis; when used in combination with midazolam or triazolam, it can reduce the clearance of the two and enhance their effects. 9. This product can obstruct the enterohepatic circulation of sex hormones, and combined with oral contraceptives can reduce their efficacy.